Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.
Rivero
Ana
A
Department of Haematology, Hospital 12 de Octubre, Madrid, Spain.
Rapado
Inmaculada
I
Tomás
José F
JF
Montalbán
Carlos
C
de Oña
Raquel
R
Paz-Carreira
José
J
Canales
Miguel
M
Martínez
Rafael
R
Sánchez-Godoy
Pedro
P
de Sevilla
Alberto Fernández
AF
de la Serna
Javier
J
Martínez-López
Joaquín
J
D000483:Alleles; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D004252:DNA Mutational Analysis; D003842:Deoxycytidine Kinase / Q000235:genetics*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000235:genetics; D015971:Gene Expression Regulation, Enzymologic; D015973:Gene Expression Regulation, Leukemic; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000235:genetics*; D008231:Lymphopenia / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
D003842:Deoxycytidine Kinase; D014740:Vidarabine; C024352:fludarabine